Powered by HealthTechMovers.com
We added 3 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
CVS Health, CVS
Summary: CVS Health Corporation is a pharmacy innovation company. Its offerings include pharmacy benefit management services, mail order, retail and specialty pharmacy, disease management programs, and retail clinics. The Company serves employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names. CVS Health Corporation, formerly known as CVS Caremark Corporation, is headquartered in Woonsocket, Rhode Island.
- Last Price: $70.74
- Price Change: $0.75, 1.07%
- Yearly Gain: -24.89%
- Market Cap: $89.73B
- P/E Ratio: 23.053
Here are 3rd party ratings for CVS:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 12% (220 out of 250)
What is the sentiment on the street regarding CVS Health ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in CVS or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CVS before you decide to make any investment.
Click here for chart >>
Trevi Therapeutics, TRVI
Summary: Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics Inc. is based in New Haven, Connecticut.
- Last Price: $2.16
- Price Change: -$0.08, -3.57%
- Yearly Gain: -9.68%
- Market Cap: $134.56M
- P/E Ratio: -5.954
Here are 3rd party ratings for TRVI:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Top 44% (109 out of 250)
What is the sentiment on the street regarding Trevi Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in TRVI or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on TRVI before you decide to make any investment.
Click here for chart >>
Chimerix, CMRX
Summary: Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina.
- Last Price: $1.46
- Price Change: $0.01, 0.69%
- Yearly Gain: -18.54%
- Market Cap: $128.45M
- P/E Ratio: 0.724
Here are 3rd party ratings for CMRX:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 24% (59 out of 250)
What is the sentiment on the street regarding Chimerix ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Very Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Neutral
If you are interested in CMRX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CMRX before you decide to make any investment.
Click here for chart >>
Thanks for reading!